Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Experts from Yale University have discovered an alarming syndrome linked to the mRNA Covid vaccines. The previously-unknown condition - dubbed 'post-vaccination syndrome' - appears to cause brain ...

TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders.